首页|Fourth Affiliated Hospital Reports Findings in Bladder Cancer (A platelet-relate d signature for predicting the prognosis and immunotherapy benefit in bladder ca ncer based on machine learning combinations)
Fourth Affiliated Hospital Reports Findings in Bladder Cancer (A platelet-relate d signature for predicting the prognosis and immunotherapy benefit in bladder ca ncer based on machine learning combinations)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Bladder Can cer is the subject of a report. According to news reporting out of Suzhou, Peopl e’s Republic of China, by NewsRx editors, research stated, “Bladder cancer carri es a large societal burden, with over 570,000 newly diagnosed cases and 210,000 deaths globally each year. Platelets play vital functions in tumor progression a nd therapy benefits.” Our news journalists obtained a quote from the research from Fourth Affiliated H ospital, “We aimed to construct a platelet-related signature (PRS) for the clini cal outcome of bladder cancer cases. Ten machine learning techniques were used i n the integrative operations to build PRS using the datasets from The Cancer Gen ome Atlas (TCGA), gene series expression (GSE)13507, GSE31684, GSE32894 and GSE4 8276. A number of immunotherapy datasets and prediction scores, including GSE910 61, GSE78220, and IMvigor210, were utilized to assess how well the PRS predicted the benefit of immunotherapy. Vitro experiment was performed to verify the role of a1C-tubulin (TUBA1C) in bladder cancer. Enet (alpha =0.4) algorithm-based PR S had the highest average C-index of 0.73 and it was suggested as the optimal PR S. PRS acted as an independent risk factor for bladder cancer and patients with high PRS score portended a worse overall survival rate, with the area under the curve of 1-, 3- and 5-year operating characteristic curve being 0.754, 0.779 and 0.806 in TCGA dataset. A higher level of immune-activated cells, cytolytic func tion and T cell co-stimulation was found in the low PRS score group. Low PRS sco re demonstrated a higher tumor mutation burden score and programmed cell death p rotein 1 & cytotoxic T-lymphocyte associated protein 4 immunopheno score, lower tumor immune dysfunction and exclusion score, intratumor heterogene ity score and immune escape score in bladder cancer, suggesting the PRS as an in dicator for predicting immunotherapy benefits. Vitro experiment showed that TUBA 1C was upregulated in bladder cancer and knockdown of TUBA1C obviously suppresse d tumor cell proliferation.”
SuzhouPeople’s Republic of ChinaAsiaBladder CancerCancerCyborgsDrugs and TherapiesEmerging TechnologiesG eneticsHealth and MedicineImmunotherapyMachine LearningOncologyRisk an d Prevention
NETL
NSTL
